



IN THE CLAIMS

Please amend the claims as follows:

Claims 1-43 (Cancelled)

44. (Currently Amended) A medical product comprising a dry powder dose comprising at least one of tiotropium and physiologically acceptable salts thereof directly loaded into a container adapted for administration by a dry powder inhaler, wherein

the medical product comprises a dry, moisture-tight seal foil fixed to a dry, moisture tight container, barrier seal constitutes the container;

the dry, moisture-tight container and the moisture tight seal foil together form a dry, moisture-tight barrier seal of the container that prevents ingress of moisture into the powder dose whereby an original fine particle fraction of the powder dose is preserved for at least seven days,

the medical product is designed so as to provide gradual aerosolization of the dry powder dose during delivery, and

a delivered fine particle dose of said at least one of tiotropium and physiologically acceptable salts thereof from said medical product is generally independent of variations in ambient humidity conditions.

45. (Previously Presented) The medical product according to claim 44, wherein the original fine particle fraction of the powder dose is preserved for at least fourteen days.

46. (Previously Presented) The medical product according to claim 44, wherein the container itself does not emit water.

47. (Previously Presented) The medical product according to claim 44, wherein the delivered fine particle dose of at least one of tiotropium and physiologically acceptable salts thereof constitutes at least 56 % of a delivered dose.

48. (Previously Presented) The medical product according to claim 44, wherein the delivered fine particle dose of at least one of tiotropium and physiologically acceptable salts thereof constitutes at least 47 % of a metered dose.

49. (Cancelled)

50. (Previously Presented) The medical product according to claim 44, wherein the at least one of tiotropium and physiologically acceptable salts thereof consists of one or more physiologically acceptable salts of tiotropium.

51. (Previously Presented) The medical product according to claim 44, wherein said dose further comprises lactose.

52. (Currently Amended) The medical product according to claim 44, wherein the dry, moisture-tight barrier seal is formed ~~or of~~ flat aluminum foils, optionally laminated with polymers.

53. (Currently Amended) The medical product according to claim 44, wherein a cavity molded from a polymer material ~~selected to give the container moisture-tight barrier seal properties~~ constitutes the container.

54. (Cancelled)

55. (Cancelled)

56. (Currently Amended) The medical product according to claim 44, wherein the ~~container~~ medical product is a separate part adapted for insertion into a dry powder inhaler

57. (Cancelled)

58. (Previously Presented) The medical product according to claim 44, wherein the medical product is adapted for use in the treatment of respiratory disorders.

59. (Currently Amended) A medical product comprising at least one of tiotropium and physiologically acceptable salts thereof and at least one additional active pharmaceutical

ingredient and optionally including at least one excipient in a dry powder medical combination dose directly loaded into a container, wherein

the medical product comprises a dry, moisture-tight seal foil fixed to a dry, moisture tight container, barrier seal constitutes the container;

the dry, moisture-tight container and the moisture tight seal foil together form a dry, moisture-tight barrier seal of the container that prevents ingress of moisture into the powder dose whereby an original fine particle fraction of the powder dose is preserved for at least seven days,

the medical product is designed so as to provide gradual aerosolization of the dry powder dose during delivery,

the combination dose is adapted for administration by a dry powder inhaler,

a delivered fine particle dose of the combination dose is generally independent of variations in ambient humidity conditions, and

the at least one additional active pharmaceutical ingredient is selected from inhalable steroids, nicotinamide derivatives, beta-agonists, beta-mimetics, anti-histamines, adenosine A_{2A} receptors, PDE4 inhibitors, and dopamine D₂ receptor agonists.

60. (Previously Presented) The medical product according to claims 59, wherein the original fine particle fraction of the combination dose is preserved for at least fourteen days.

61. (Previously Presented) The medical product according to claim 59, wherein the container itself does not emit water.

62. (Previously Presented) The medical product according to claim 59, wherein the delivered fine particle dose of the combination dose constitutes at least 56 % of a delivered dose.

63. (Previously Presented) The medical product according to claim 59, wherein the delivered fine particle dose of the combination dose constitutes at least 47 % of a metered dose.

64. (Cancelled)

65. (Previously Presented) The medical product according to claim 59, wherein the at least one of tiotropium and physiologically acceptable salts thereof consists of one or more physiologically acceptable salts of tiotropium.

66. (Previously Presented) The medical product according to claim 59, comprising excipient lactose.

67. (Currently Amended) The medical product according to claim 59, wherein the dry, moisture-tight barrier seal is formed ~~or of~~ flat aluminum foils, optionally laminated with polymers.

68. (Currently Amended) The medical product according to claim 59, wherein a cavity molded from a polymer material ~~selected to give the container moisture-tight barrier seal properties~~ constitutes the container.

69. (Cancelled)

70. (Cancelled)

71. (Currently Amended) The medical product according to claim 59, wherein the ~~container medical product~~ is a separate part adapted for insertion into a dry powder inhaler.

72. (Previously Presented) The medical product according to claim 59, wherein the container is a separate part comprising a primary part adapted for insertion into a dry powder inhaler and a secondary part enclosing the primary part in a moisture-tight package.

73. (Previously Presented) The medical product according to claim 59, wherein the medical product is adapted for use in the treatment of respiratory disorders.